Cargando…
Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy
Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900976/ https://www.ncbi.nlm.nih.gov/pubmed/31827897 http://dx.doi.org/10.2144/fsoa-2019-0086 |
_version_ | 1783477434344013824 |
---|---|
author | Kumar, Chaitanya Bagga, Jasmine Chiliveru, Srikanth Kohli, Sakshi Bharadwaj, Asmi Jain, Minish Inamdar, Shriram Sharan, Bandana |
author_facet | Kumar, Chaitanya Bagga, Jasmine Chiliveru, Srikanth Kohli, Sakshi Bharadwaj, Asmi Jain, Minish Inamdar, Shriram Sharan, Bandana |
author_sort | Kumar, Chaitanya |
collection | PubMed |
description | Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN(®) in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life. |
format | Online Article Text |
id | pubmed-6900976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-69009762019-12-11 Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy Kumar, Chaitanya Bagga, Jasmine Chiliveru, Srikanth Kohli, Sakshi Bharadwaj, Asmi Jain, Minish Inamdar, Shriram Sharan, Bandana Future Sci OA Case Report Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN(®) in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life. Future Science Ltd 2019-10-29 /pmc/articles/PMC6900976/ /pubmed/31827897 http://dx.doi.org/10.2144/fsoa-2019-0086 Text en © 2019 APAC Biotech PVT Ltd This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Case Report Kumar, Chaitanya Bagga, Jasmine Chiliveru, Srikanth Kohli, Sakshi Bharadwaj, Asmi Jain, Minish Inamdar, Shriram Sharan, Bandana Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title_full | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title_fullStr | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title_full_unstemmed | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title_short | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy |
title_sort | substantial remission of prostate adenocarcinoma with dendritic cell therapy apceden(®) in combination with chemotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900976/ https://www.ncbi.nlm.nih.gov/pubmed/31827897 http://dx.doi.org/10.2144/fsoa-2019-0086 |
work_keys_str_mv | AT kumarchaitanya substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT baggajasmine substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT chiliverusrikanth substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT kohlisakshi substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT bharadwajasmi substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT jainminish substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT inamdarshriram substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy AT sharanbandana substantialremissionofprostateadenocarcinomawithdendriticcelltherapyapcedenincombinationwithchemotherapy |